MBX Biosciences' Phase 3 hypoparathyroidism trial enrolls, obesity pipeline advancesNov 16Clinical readoutcanvuparatideMBX BiosciencesUpdated
Altimmune reports Q3 2026 results as pemvidutide programs advance in MASH and AUDNov 12Quarterly updateAltimmune, Inc.MetaVia Inc.
Madrigal posts first profitable quarter as Rezdiffra tops $1 billion in 2026 salesNov 3Quarterly updateMadrigal Pharmaceuticals, Inc.resmetirom
Madrigal registers two resmetirom studies: Phase 1b in MASH/HFpEF and Phase 4 drug-interaction trialOct 16Weekly roundup, 2 itemsMadrigal Pharmaceuticals, Inc.resmetirom
RadNet lists ultrasound biomarker study for resmetirom eligibility, not yet recruitingOct 6Trial updateMadrigal Pharmaceuticals, Inc.resmetirom
Madrigal registers Phase 4 safety study of Rezdiffra with diabetes drugs in MASH patientsSep 29Trial updateMadrigal Pharmaceuticals, Inc.resmetirom
Madrigal registers new Phase 1b trial testing resmetirom in MASH patients with HFpEFSep 21Trial updateMadrigal Pharmaceuticals, Inc.resmetirom
Madrigal registers pediatric Phase 2a trial of resmetirom for MASHAug 13Trial updateMadrigal Pharmaceuticals, Inc.resmetirom
Madrigal advances MGL-2086 into Phase 1, adds resmetirom patents, posts Q2 2026 resultsJul 30Quarterly updateMadrigal Pharmaceuticals, Inc.resmetirom